Neuron Specific Enolase in Ventricular Assist Device Recipients
- Conditions
- Left Ventrucular Assist DeviceAdvanced Heart Failure
- Registration Number
- NCT01643551
- Lead Sponsor
- University of Minnesota
- Brief Summary
An observational study of neuron specific enolase, as a marker of reperfusion injury, in LVAD recipients before and following VAD implantation.
- Detailed Description
Patients eligible for left ventricular assist device (LVAD) typically have severe heart failure, which is characterized by poor cardiac output. The relatively abrupt increase in cardiac output that follows implant of a LVAD may cause reperfusion injury. Furthermore, selected patients may have particularly severe consequences of such injury, including refractory acidosis and vasoplegia. Neuron specific enolase (NSE) has been established as a biomarker of reperfusion injury. We hypothesize that changes in NSE following LVAD will be greater than the changes in NSE noted in a control population of patients undergoing non-VAD cardiac surgery.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 15
Group 1 - Pre-VAD implantation patients
- 18 years and older
- lanning to undergo VAD implantation Group 2 Cardiac Surgery Comparison Group
- 18 years or older
- Planning to undergo valve or coronary bypass surgery
- Acute cerebrovascular infarction
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Neuron-Specific Enolase Pre and post-surgery
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University of Minnesota Medical Center-Fairview
🇺🇸Minneapolis, Minnesota, United States